Searchable abstracts of presentations at key conferences in endocrinology

ea0005p128 | Endocrine Tumours and Neoplasia | BES2003

CYP27b and CYP24 expression combine to determine 1,25 Dihydroxyvitamin D3 insensitivity in breast cancer cells

Townsend K , Banwell C , Stewart P , Hewison M , Campbell M

To dissect mechanisms which result in 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) insensitivity we have compared the antiproliferative actions of 1,25(OH)2D3 in a range of malignant breast cell lines (ZR-75-1, T-47D, MCF-7, MCF-7Res and MDA-MB-231) and the non-malignant breast epithelial cells MCF-12A cells. All the malignant cell lines displayed greater resistance than MCF-12A cells to 1,25(OH)2D3. For ex...

ea0003oc11 | Endocrine Neoplasia | BES2002

CYP24 action: An intrinsic mechanism of resistance in breast and prostate cancer cells

Moore J , Miles A , Townsend K , Colston K , Stewart P , Hewison M , Campbell M

We hypothesised that normal regulation of 25(OH)D3-24-hydroxylase (encoded by CYP24) determines the autocrine/paracrine action of 1,25(OH)2D3 in normal breast and prostate epithelial cells. Furthermore, these processes are compromised in malignancy.We therefore studied the regulation of CYP24, amongst a panel of breast and prostate cancer cell lines (ZR-75-1, T47-D, MCF-7, MDA-MB-231 breast cells and LNCaP, PC-3 and DU-145 prostate cells) that display d...

ea0019oc11 | Neuroendocrine and Steroids | SFEBES2009

Familial and phenotypic associations of the aldosterone renin ratio in the general population

Alvarez-Madrazo S , Padmanabhan S , Wallace M , Campbell M , Smith J , Friel E , Dorrian C , Keavney B , Davies E , Connell J

Recent studies in non-hypertensive patients have shown aldosterone renin ratio (ARR) to be heritable and associated with increased risk of blood pressure (BP) elevation. Furthermore, a raised ARR is present in 10% of hypertensive patients although the precise significance of this is unclear. The magnitude of heritability of ARR will indicate the influence of genetic determination of the phenotype. In this study, we estimated the heritabilities of the components of ARR and the ...

ea0009p84 | Endocrine tumours and neoplasia | BES2005

DNA array analysis of a vitamin D-resistant variant of MCF-7 breast cancer cells

Townsend K , Colston K , Bujalska I , Campbell M , Hewison M

The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3) is a potent antiproliferative agent with putative applications in the treatment of common cancers. However, doses of 1,25D3 required to achieve tangible anticancer responses also stimulate unwanted calciotropic effects. Data suggest that this is due, in part, to acquired resistance to 1,25D3 in cancer cells, particularly in more aggressive tumours. To investigate this fu...

ea0011p749 | Steroids | ECE2006

Hydrocortisone replacement therapy- the controversy continues…

Freel M , Thomson A , Devers M , Campbell K , Grant D , Wallace M , Connell J

Although hydrocortisone is the standard replacement therapy for primary or secondary adrenal insufficiency (AI), there are limited data on dosage requirements and the value of salivary monitoring in this patient group. We assessed inter-individual variability in cortisol metabolism and relationships between plasma and salivary cortisol profiles in 27 patients. Ten (3 male) patients had primary AI and 17 (8 male) secondary AI. Salivary and plasma cortisol levels were measured a...

ea0007oc23 | Endocrine tumours | BES2004

Expression of vitamin D metabolism and signalling components in breast tumours compared to paired normals

Townsend K , Guy M , Colston K , Mansi J , Campbell M , Hewison M

Recent studies have highlighted a role for vitamin D in the prevention and treatment of breast cancer. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), is a potent antiproliferative/proapoptotic agent and its nuclear receptor (vitamin D receptor, VDR) is well expressed in breast tissue. We have investigated whether or not VDR signalling in breast tumours is due to systemic (renal) 1,25D3 or, as with oestrogens, there is local sy...

ea0003oc9 | Endocrine Neoplasia | BES2002

Breast cancer cells express the vitamin D activating enzyme 1alpha-hydroxylase

Townsend K , Evans K , Hughes S , Mork|#Hansen C , Colston K , Campbell M , Hewison M

Studies in vitro have highlighted the potent anti-cancer effects of the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3). However, the in vivo application of 1,25D3 and its synthetic analogs remains problematical due to persistent hypercalcaemic side-effects. Recent studies have shown that it may be possible to overcome this in an autocrine fashion via extra-renal synthesis of 1,25D3. In particular, analysis of prostate and co...